Here’s What Analysts Are Saying About Bristol-Myers Squibb Company (BMY)

Core Insights - Bristol-Myers Squibb Company (NYSE:BMY) is recognized as a strong investment opportunity by hedge funds, with multiple analysts raising price targets and maintaining positive ratings on the stock [1][2][3] Group 1: Analyst Ratings and Price Targets - Bernstein reiterated a Hold rating on Bristol-Myers Squibb with a price target of $58.00 as of February 10 [1] - Morgan Stanley raised its price target from $37 to $40 while maintaining an Underweight rating, citing that the 2026 revenue and EPS guidance exceeded consensus due to a higher-than-expected Eliquis guide [1] - BofA increased its price target from $64 to $68 and maintained a Buy rating, noting that the company delivered fiscal Q4 and FY26 guidance beats, emphasizing that Bristol-Myers is a "pipeline story" [2] - Guggenheim raised its price target from $62 to $72, maintaining a Buy rating and increasing the odds of success for key drugs iber/mezi and milvexian to 90% [3] Group 2: Company Overview - Bristol-Myers Squibb is a biopharmaceutical company focused on discovering, developing, and delivering advanced medicines for serious diseases across various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience [4]